Haisco Pharmaceutical Group has acquired Chinese rights to products developed by Pneuma Respiratory in a deal that included a $10 million equity investment in Pneuma, the company said. In addition to the equity investment, Haisco will fund Chinese regulatory filings.
In July 2018, Pneuma Respiratory said that it had completed a series A fundraising round that raised $8.3 million for development of products based on its Pneumahaler digital soft mist inhaler. According to Pneuma, the company plans to develop off-patent asthma and COPD drugs for delivery by the Pneumahaler system.
Pneuma Respiratory CEO and Cofounder Eric Hunter commented, “We look forward to working with Haisco to introduce Pneuma’s pharmaceutical products in China. As a prominent pharmaceutical company in China, the investment is a vote of confidence in our team and our approach to improving drug effectiveness.”
Read the Pneuma Respiratory press release.
